BNTC SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Sep 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Mar 20, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Feb 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Sep 22, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

Oct 28, 2026

8-K

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

Oct 5, 2026

8-K

Benitec Biopharma Inc. Completes Engagement of Ernst & Young LLP as Independent Auditor

Sep 30, 2026

8-K

Benitec Biopharma Inc. Changes Independent Registered Public Accounting Firm

Sep 24, 2026

8-K

Benitec Biopharma Reports Full Year 2026 Financial Results and Provides BB-301 Clinical and Regulatory Updates

Sep 14, 2026

8-K

Benitec Biopharma Inc. Announces Board of Directors Changes

May 29, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 1,481,481

Feb 10, 2026

424B5

REGISTERED OFFERING

Nov 6, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Leerink Partners, TD Cowen, Evercore ISI

Nov 5, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 900,000 | Share price: $13

Jun 2, 2025

424B5

REGISTERED OFFERING

Mar 26, 2025

424B5

ATM | Offering amount: $75,000,000

Oct 15, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3

September 2026 SHELF

Sep 14, 2026

S-3

SHARE RESALE REGISTRATION

Jan 30, 2026

S-3

September 2025 SHELF | Offering amount: $200,000,000

Sep 22, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 900,000 | Share price: $13

May 23, 2025

S-3

SHELF | Offering amount: $125,000,000.00 EFFECTIVE

Nov 1, 2024

S-8

Registration

Oct 1, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Oct 20, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Nov 12, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Oct 14, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 14, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Nov 14, 2024

Ownerships

TYPE

HEADLINE

FILED AT

S-3

Form S-3 - Registration statement under Securities Act of 1933

Sep 14, 2026

BUCHI J KEVIN (Reporting)

Jun 30, 2026

Friedman David Matthew (Reporting)

May 28, 2026

Friedman David Matthew (Reporting)

May 28, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Jan 30, 2026

SCHEDULE 13G/A

FRANKLIN RESOURCES INC (Filed by)

Jan 29, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 22, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 3, 2026

CORRESP

Form CORRESP - Correspondence

Mar 20, 2026

LETTER

Form UPLOAD - SEC-generated letter

Feb 24, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 11, 2026

CORRESP

Form CORRESP - Correspondence

Feb 6, 2026

Benitec Biopharma Inc. BNTC · SEC Filings